← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Sorrento Therapeutics, Inc.
San Diego, CA
$9,414,945
Total funding
7
Grants
Funding over time
peak $4.6M · FY2010–23$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$9,414,945 · 7
By mechanism
N01$4,590,862 · 1
R42$2,595,459 · 1
R41$2,003,801 · 4
R43$224,823 · 1
Investigators at Sorrento Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Development of In Vitro Diagnostics for the Detection of SARS-CoV-2$4,590,862
N01 · FY2023 · AI
Human monoclonal antibodies for prevention of S. aureus infections$999,189
R42 · FY2014 · AI
Human monoclonal antibodies for prevention of S. aureus infections$998,438
R42 · FY2015 · AI
Human monoclonal antibodies for prevention of S. aureus infections$300,000
R42 · FY2012 · AI
Evaluation of Staphylococcus aureus agr-based Quorum Sensing as Vaccine Candidate$300,000
R41 · FY2010 · AI
Evaluation of Staphylococcus aureus agr-based Quorum Sensing as Vaccine Candidate$300,000
R41 · FY2011 · AI
A vaccine against Clostridium difficile infections$299,999
R41 · FY2011 · AI
Anti-Pseudomonas Immunotherapy and Targeted Drug Delivery$298,668
R41 · FY2014 · AI
Human monoclonal antibodies for prevention of S. aureus infections$297,832
R42 · FY2013 · AI
A vaccine against Clostridium difficile infections$292,717
R41 · FY2012 · AI
Anti-Pseudomonas Immunotherapy and Targeted Drug Delivery$287,867
R41 · FY2015 · AI
Human Anti-WISP1 Antibodies for Treatment of Idiopathic Pulmonary Fbrosis$224,823
R43 · FY2014 · HL
Targeting of Myc-Max dimerization for the treatment of cancer$224,550
R41 · FY2014 · CA